Clinical Trial Update: Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of BDC-1001, with or without Pertuzumab, in HER2-positive metastatic breast cancer was terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BDC-1001
• Perjeta (pertuzumab)

Snippet

Sponsor: Bolt Biotherapeutics, Inc. | Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-11-20